目前为止，关于ESYT3与肿瘤之间的关联的研究很少。本研究的目的是探究ESYT3在肺腺癌（LUAD）中的分子特征和潜在作用。在本研究中，主要使用GEPIA，UALCAN，TCGA数据库和KM Plotter来研究LUAD患者中ESYT3的mRNA表达谱和预后价值。然后，我们通过cBioPortal在线工具评估了ESYT3的共表达基因，并使用Metascape进行富集分析。此外，我们通过TIMER2来探索ESYT3与免疫浸润细胞之间的关系，并使用MethSurv数据库进行甲基化分析。我们发现，基于TCGA和GEPIA数据库，ESYT3在LUAD组织中下调。ESYT3 mRNA的低表达与N分级和分期分级显著相关。GEPIA2，UALCAN数据库和KM Plotter显示，ESYT3的低表达水平与LUAD患者的不良生存相关。富集分析表明ESYT3的共表达基因在细胞分裂中高度富集。然后，我们的研究显示ESYT3与免疫浸润和免疫检查点相关。此外，在LUAD中，低ESYT3表达与低甲基化以及不良预后相关。总而言之，本研究认为ESYT3可能是LUAD的潜在预后标记和有前景的治疗靶点。版权所有© 2023年作者。由Wolters Kluwer Health, Inc.出版。

Few studies have reported the association between ESYT3 and tumors. The purpose of this study was to investigate the molecular features and potential roles of ESYT3 in lung adenocarcinoma (LUAD). In the present study, GEPIA, UALCAN, TCGA databases, and KM Plotter were primarily used to study ESYT3 mRNA expression profiles and prognostic values in patients with LUAD. Then we evaluated co-expressed genes of ESYT3 by cBioPortal online tools and performed enrichment analysis using Metascape. Moreover, the relationship between ESYT3 and immune infiltrating cells was explored via TIMER2, and MethSurv database was used to conduct methylation analysis. We found ESYT3 was downregulated in LUAD tissues based on TCGA and GEPIA databases. Low expression of ESYT3 mRNA was observed to be significantly correlated with N classification and stage classification. GEPIA2, UALCAN databases and KM Plotter showed that low expression levels of ESYT3 was associated with poor survival in LUAD patients. The enrichment analysis indicated that co-expressed genes of ESYT3 were highly enriched in cell division. Then, our study showed ESYT3 was correlated with immune infiltration and immune checkpoints. Additionally, hypomethylation was associated with low ESYT3 expression and poor prognosis in LUAD. In conclusion, this study suggested ESYT3 could be a potential prognostic marker and a promising therapeutic target in LUAD.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.